title: Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.
abstract: New improved vaccines are needed for control of both bovine and human tuberculosis. Tuberculosis protein vaccines have advantages with regard to safety and ease of manufacture, but efficacy against tuberculosis has been difficult to achieve. Protective cellular immune responses can be preferentially induced when antigens are displayed on small particles. In this study, Escherichia coli and Lactococcus lactis were engineered to produce spherical polyhydroxybutyrate (PHB) inclusions which displayed a fusion protein of Mycobacterium tuberculosis, antigen 85A (Ag85A)-early secreted antigenic target 6-kDa protein (ESAT-6). L. lactis was chosen as a possible production host due its extensive use in the food industry and reduced risk of lipopolysaccharide contamination. Mice were vaccinated with PHB bead vaccines with or without displaying Ag85A-ESAT-6, recombinant Ag85A-ESAT-6, or M. bovis BCG. Separate groups of mice were used to measure immune responses and assess protection against an aerosol M. bovis challenge. Increased amounts of antigen-specific gamma interferon, interleukin-17A (IL-17A), IL-6, and tumor necrosis factor alpha were produced from splenocytes postvaccination, but no or minimal IL-4, IL-5, or IL-10 was produced, indicating Th1- and Th17-biased T cell responses. Decreased lung bacterial counts and less extensive foci of inflammation were observed in lungs of mice receiving BCG or PHB bead vaccines displaying Ag85A-ESAT-6 produced in either E. coli or L. lactis compared to those observed in the lungs of phosphate-buffered saline-treated control mice. No differences between those receiving wild-type PHB beads and those receiving recombinant Ag85A-ESAT-6 were observed. This versatile particulate vaccine delivery system incorporates a relatively simple production process using safe bacteria, and the results show that it is an effective delivery system for a tuberculosis protein vaccine.
authors.affiliation: AgResearch, Hopkirk Research Institute, Palmerston North, New Zealand.
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Parlane
authors.forename: Katrin
authors.initials: K
authors.lastname: Grage
authors.forename: Jun
authors.initials: J
authors.lastname: Mifune
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Basaraba
authors.forename: D Neil
authors.initials: DN
authors.lastname: Wedlock
authors.forename: Bernd H A
authors.initials: BH
authors.lastname: Rehm
authors.forename: Bryce M
authors.initials: BM
authors.lastname: Buddle
mesh_terms: D000217:Acyltransferases / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D058491:Bacterial Load; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage* / Q000378:metabolism; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D005260:Female; D006885:Hydroxybutyrates / Q000008:administration & dosage* / Q000378:metabolism; D007111:Immunity, Cellular; D013294:Lactococcus lactis / Q000235:genetics / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008863:Microspheres; D011091:Polyesters / Q000008:administration & dosage* / Q000378:metabolism; D000091402:Prohibitins; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D013154:Spleen / Q000276:immunology; D014376:Tuberculosis / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D000094122:Polyhydroxybutyrates
chemical_list: D000217:Acyltransferases; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D016207:Cytokines; D004337:Drug Carriers; D006885:Hydroxybutyrates; D011091:Polyesters; D000091402:Prohibitins; D011993:Recombinant Fusion Proteins; D032581:Tuberculosis Vaccines; C093276:ESAT-6 protein, Mycobacterium tuberculosis; C000717328:PHB protein, human; C003182:poly-beta-hydroxybutyrate; D000094122:Polyhydroxybutyrates; C112580:antigen 85A, Mycobacterium tuberculosis
references.citation: J Control Release. 1998 Jun;54(1):49-59
references.pmid: 9741903
references.citation: Appl Environ Microbiol. 2009 Dec;75(24):7739-44
references.pmid: 19837843
references.citation: Appl Environ Microbiol. 2011 Dec;77(24):8516-22
references.pmid: 21984246
references.citation: PLoS One. 2010 Jun 25;5(6):e11277
references.pmid: 20593018
references.citation: Curr Gene Ther. 2010 Feb;10(1):34-45
references.pmid: 20156189
references.citation: Clin Dev Immunol. 2011;2011:617892
references.pmid: 21461375
references.citation: Appl Environ Microbiol. 2009 Sep;75(17):5461-6
references.pmid: 19581473
references.citation: Science. 1997 May 30;276(5317):1420-2
references.pmid: 9162010
references.citation: J Immunol. 2008 Mar 1;180(5):3569-77
references.pmid: 18292584
references.citation: Infect Immun. 2005 Jun;73(6):3540-6
references.pmid: 15908383
references.citation: Int Immunopharmacol. 2008 Dec 20;8(13-14):1773-80
references.pmid: 18801462
references.citation: J Infect Dis. 1999 Mar;179(3):637-45
references.pmid: 9952370
references.citation: Expert Rev Vaccines. 2007 Oct;6(5):797-808
references.pmid: 17931159
references.citation: J Biotechnol. 2008 Apr 30;134(3-4):266-74
references.pmid: 18367283
references.citation: Int J Biol Macromol. 1999 Jun-Jul;25(1-3):111-21
references.pmid: 10416657
references.citation: Immunol Cell Biol. 2002 Aug;80(4):346-50
references.pmid: 12121223
references.citation: Expert Rev Vaccines. 2010 Oct;9(10):1121-4
references.pmid: 20923262
references.citation: Microbiol Res. 2011 Feb 20;166(2):111-20
references.pmid: 20227266
references.citation: Infect Immun. 1994 Sep;62(9):3679-87
references.pmid: 7520418
references.citation: Infect Immun. 1997 Jul;65(7):2587-92
references.pmid: 9199424
references.citation: Lancet. 2010 Jun 12;375(9731):2110-9
references.pmid: 20488515
references.citation: Methods. 2006 Sep;40(1):118-24
references.pmid: 16997719
references.citation: Vaccine. 2009 Nov 16;27(49):6862-8
references.pmid: 19755144
references.citation: Curr Drug Deliv. 2006 Oct;3(4):379-88
references.pmid: 17076640
references.citation: J Biotechnol. 2007 Nov 1;132(3):238-45
references.pmid: 17420063
references.citation: Immunology. 2003 Apr;108(4):548-55
references.pmid: 12667217
references.citation: Scand J Immunol. 2010 Oct;72(4):332-8
references.pmid: 20883318
references.citation: Vaccine. 2008 Nov 18;26(49):6189-99
references.pmid: 18852005
references.citation: Curr Opin Immunol. 2010 Jun;22(3):374-84
references.pmid: 20471231
references.citation: Future Microbiol. 2011 Feb;6(2):161-77
references.pmid: 21366417
references.citation: Curr Opin Microbiol. 2010 Feb;13(1):106-12
references.pmid: 20079678
references.citation: J Immunol. 2005 Mar 15;174(6):3570-9
references.pmid: 15749894
references.citation: Expert Opin Biol Ther. 2011 Mar;11(3):261-7
references.pmid: 21204744
references.citation: Infect Immun. 2000 Feb;68(2):791-5
references.pmid: 10639447
references.citation: BMC Biotechnol. 2007 Jan 04;7:3
references.pmid: 17204164
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12434-9
references.pmid: 17640915
references.citation: Nat Rev Microbiol. 2005 Aug;3(8):656-62
references.pmid: 16012514
references.citation: Appl Environ Microbiol. 1988 Aug;54(8):1977-82
references.pmid: 16347708
references.citation: Clin Vaccine Immunol. 2008 May;15(5):765-72
references.pmid: 18337375
references.citation: J Immunol. 2007 Jul 1;179(1):522-31
references.pmid: 17579073
references.citation: Emerg Infect Dis. 1998 Jan-Mar;4(1):59-70
references.pmid: 9452399
references.citation: Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17
references.pmid: 20167847
references.citation: Nat Genet. 2010 Jun;42(6):498-503
references.pmid: 20495566
references.citation: Hum Vaccin. 2011 Jan 1;7(1):106-9
references.pmid: 21263226
references.citation: Biotechnol Lett. 2009 Jan;31(1):131-7
references.pmid: 18800192
references.citation: Clin Vaccine Immunol. 2011 Jan;18(1):95-104
references.pmid: 21084465
references.citation: J Mol Microbiol Biotechnol. 2008;14(1-3):48-58
references.pmid: 17957110
references.citation: Nat Med. 2004 Nov;10(11):1240-4
references.pmid: 15502839
references.citation: Nat Immunol. 2007 Apr;8(4):369-77
references.pmid: 17351619
references.citation: Infect Immun. 1996 Jan;64(1):16-22
references.pmid: 8557334
references.citation: Semin Immunopathol. 2010 Mar;32(1):79-90
references.pmid: 20112107
references.citation: J Biotechnol. 2010 May 3;147(1):31-6
references.pmid: 20214931
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):870-5
references.pmid: 19139407
references.citation: Appl Environ Microbiol. 2009 Jul;75(14):4668-75
references.pmid: 19465535